A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection
dc.contributor.author | Andreu-Ballester, Juan Carlos | |
dc.contributor.author | Galindo-Regal, Lorena | |
dc.contributor.author | Cuéllar Del Hoyo, María Del Carmen | |
dc.contributor.author | López-Chuliá, Francisca | |
dc.contributor.author | García-Ballesteros, Carlos | |
dc.contributor.author | Fernández-Murga, Leonor | |
dc.contributor.author | Llombart-Cussac, Antonio | |
dc.contributor.author | Domínguez-Márquez, María Victoria | |
dc.contributor.editor | Klasse, P. J. | |
dc.contributor.editor | Mostafa, Mai | |
dc.date.accessioned | 2024-07-17T11:36:49Z | |
dc.date.available | 2024-07-17T11:36:49Z | |
dc.date.issued | 2024-05-18 | |
dc.description.abstract | Background: The COVID-19 pandemic is the biggest global health problem in the last hundred years. The efficacy of the vaccine to protect against severe disease is estimated to be 70–95% according to the studies carried out, although there are aspects of the immune response to the vaccine that remain unclear. Methods: Humoral and cellular immunity after the administration of three doses of the Pfizer–BioNTech and Oxford AstraZeneca vaccines against SARS-CoV-2 over one year and the appearance of post-vaccination COVID-19 were studied. SARS-CoV-2 IgG and IgA antibodies, αβ and γδ T-cell subsets, and their differentiation stages and apoptosis were analyzed. Results: Anti-SARS-CoV-2 IgG and IgA antibodies showed a progressive increase throughout the duration of the study. This increase was the greatest after the third dose. The highest levels were observed in subjects who had anti-SARS-CoV-2 antibodies prior to vaccination. There was an increase in CD4+ αβ, CD8+ γδ and TEM CD8+ γδ T cells, and a decrease in apoptosis in CD4+ CD8+ and CD56+ αβ and γδ T cells. Post-vaccination SARS-CoV-2 infection was greater than 60%. The symptoms of COVID-19 were very mild and were related to a γδ T cell deficit, specifically CD8+ TEMRA and CD56+ γδ TEM, as well as lower pre-vaccine apoptosis levels. Conclusions: The results unveil the important role of γδ T cells in SARS-CoV-2-vaccine-mediated protection from the disease. | |
dc.description.department | Depto. de Microbiología y Parasitología | |
dc.description.faculty | Fac. de Farmacia | |
dc.description.fundingtype | Pagado por el autor | |
dc.description.refereed | TRUE | |
dc.description.sponsorship | REACT-EU programme | |
dc.description.sponsorship | Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain) | |
dc.description.status | pub | |
dc.identifier.citation | Andreu-Ballester, Juan Carlos, et al. «A Low Number of Baselines Γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection». Vaccines, vol. 12, n.o 5, mayo de 2024, p. 553. www.mdpi.com, https://doi.org/10.3390/vaccines12050553. | |
dc.identifier.doi | 10.3390/vaccines12050553 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.officialurl | https://www.mdpi.com/2076-393X/12/5/553 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/106814 | |
dc.issue.number | 5 | |
dc.journal.title | Vaccines (Basel) | |
dc.language.iso | eng | |
dc.page.initial | 553 | |
dc.publisher | MDPI | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | en |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject.cdu | 579.6 | |
dc.subject.cdu | 615.28 | |
dc.subject.cdu | 576.8 | |
dc.subject.keyword | SARS-CoV-2 | |
dc.subject.keyword | vaccine | |
dc.subject.keyword | antibodies | |
dc.subject.keyword | αβ T cells | |
dc.subject.keyword | γδ T cells | |
dc.subject.ucm | Microbiología (Farmacia) | |
dc.subject.ucm | Parasitología (Farmacia) | |
dc.subject.unesco | 32 Ciencias Médicas | |
dc.subject.unesco | 3207.12 Parasitología | |
dc.title | A Low Number of Baselines γδ T Cells Increases the Risk of SARS-CoV-2 Post-Vaccination Infection | |
dc.type | journal article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 12 | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 6c555fb4-e29c-4463-8062-a9699fcebaa6 | |
relation.isAuthorOfPublication.latestForDiscovery | 6c555fb4-e29c-4463-8062-a9699fcebaa6 |
Download
Original bundle
1 - 1 of 1
Loading...
- Name:
- ANDREU ET AL 2024 VACCINES.pdf
- Size:
- 4.27 MB
- Format:
- Adobe Portable Document Format